Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan-Dec:21:15330338221106563.
doi: 10.1177/15330338221106563.

Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab

Fei Shen  1 , Weidong Shen  1
Affiliations
Review

Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab

Fei Shen et al. Technol Cancer Res Treat. 2022 Jan-Dec.

Abstract

Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of clonal plasma cells. Although advances in treatment have markedly improved survival outcomes for patients with MM, this disease is still considered incurable owing to its high incidence of relapse and refractoriness. Isatuximab is an anti-CD38 monoclonal antibody that can induce apoptosis in myeloma cells through a variety of mechanisms. Many clinical studies have demonstrated the efficacy and efficiency of isatuximab in both relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma, leading to its approval for the treatment of adults with RRMM in combination therapies. In this review, the structure, mechanisms of action, pharmacokinetics, pharmacogenetics, and safety profile of isatuximab in MM are summarized. Additionally, isatuximab is compared with daratumumab in terms of mechanism and efficacy.

Keywords: anti-CD38 antibody; daratumumab; isatuximab; monoclonal antibody; multiple myeloma; relapsed/refractory.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676-681. doi: 10.1053/j.seminoncol.2016.11.004. - DOI - PMC - PubMed
    1. Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443-2448. doi: 10.1038/leu.2017.138. - DOI - PubMed
    1. Saltarella I, Desantis V, Melaccio A, et al. Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma. Cells. 2020;9(1):167. doi: 10.3390/cells9010167. - DOI - PMC - PubMed
    1. Moreno L, Perez C, Zabaleta A, et al. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res. 2019;25(10):3176-3187. doi: 10.1158/1078-0432.CCR-18-1597. - DOI - PubMed
    1. Podar K, Leleu X. Relapsed/refractory multiple myeloma in 2020/2021 and beyond. Cancers. 2021;13(20):5154. doi: 10.3390/cancers13205154. - DOI - PMC - PubMed

MeSH terms